The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

A Harvard Business School Healthcare Alumni Association Q&A with Stephanie J. Creary, Assistant Professor of Management at ...

One of the most significant drawbacks for a brand when partnering with individual medical journal platforms is the limitation ...

Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

Despite missing the primary endpoint, SB-01 demonstrated durable clinical improvements and consistent results in the Phase ...

Gene Mack, CEO, GAIN Therapeutics, outlines how early trial results for GT-02287 are shaping the company’s strategy for ...

Following the discontinuation of ALLO-647 due to a treatment-related death, Allogene will move forward with a streamlined ...

Organizations commonly navigate outdated systems that make collaboration harder and breakthroughs slower, causing delays, ...

Medipost transitioned from cord blood banking to developing stem cell therapies, focusing on knee osteoarthritis and other ...

Computational chemistry combined with AI technologies has become a powerful tool for assessing small molecule properties, ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...